A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine

Frontiers in Psychiatry

Serenella Tolomeo¹  Mehran Zare-Bidoky²  Marsha E. Bates³  Anna Zilverstand⁴  Henrietta Bowden-Jones⁵  Douglas Steele⁶  Scott J. Moeller⁷  Salvatore Campanella⁸  Stacey B. Daughters⁹  Martin Paulus^1,10  Hamed Ekhtiari^1,10  Christos Kouimtsidis^1,11  Dieter J. Meyerhoff^1,12  Annaketurah Ralph^1,13  Tara Rezapour^1,14  Hosna Tavakoli^1,15  David Pennington^1,16  Alex Baldacchino^1,16  Dan I. Lubman^1,17  Hugh Piercy^1,18  Victoria Manning^1,18  Shalini Arunogiri^1,18  Raimondo Bruno^2,21  Rob Hester^2,22  Valentina Lorenzetti^2,23  Antonio Verdejo-Garcia^2,24 

[1] 0Department of Psychology, National University of Singapore, Singapore, Singapore;0School of Medicine, Shahid-Sadoughi University of Medical Sciences, Yazd, Iran;1Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ, United States;1Department of Psychiatry, University of Minnesota, Minneapolis, MN, United States;2Department of Medicine, Faculty of Medicine, Imperial College, London, United Kingdom;2Medical School, University of Dundee, Ninewells Hospital, Scotland, United Kingdom;3Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, United States;3Laboratoire de Psychologie Médicale et d’Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium;4Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;4Laureate Institute for Brain Research, University of Tulsa, Tulsa, OK, United States;5Department of Psychiatry, Surrey and Borders Partnership NHS Foundation Trust, Leatherhead, United Kingdom;6DVA Medical Center and Department of Radiology and Biomedical Imaging, University of California San Francisco, School of Medicine, San Francisco, CA, United States;7School of Psychology, University of Queensland, Brisbane, QLD, Australia;8Department of Cognitive Psychology, Institute for Cognitive Sciences Studies, Tehran, Iran;9Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran;Department of Psychiatry, University of California, San Francisco, San Francisco, CA, United States;Eastern Health Clinical School Turning Point, Eastern Health, Richmond, VIC, Australia;Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia;San Francisco Veterans Affairs Health Care System (SFVAHCS), San Francisco, CA, United States;School of Medicine, University of St Andrews, Medical and Biological Science Building, North Haugh, St Andrews, United Kingdom;School of Medicine, University of Tasmania, Hobart, TAS, Australia;School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia;School of Psychology, Faculty of Health Sciences, Australian Catholic University, Canberra, ACT, Australia;Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia;

关键词: neuroscience;    addiction medicine;    treatment;    substance use disorder;    fMRI;    neuromodulation;   

DOI  :  10.3389/fpsyt.2019.00877

来源: DOAJ

【 摘 要 】

Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAM-NIG) to promote initiatives to bridge this gap. This article summarizes the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools for the assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable, and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualized prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioral outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design treatments based on multilevel targets, additional evidence from randomized trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonized protocols and data management systems, and prioritizing multi-site research that focuses on improving clinical outcomes.

【 授权许可】

Unknown